News Release

First genetic locus for voice pitch

A study from deCODE genetics reveals the first genetic locus for voice pitch

Peer-Reviewed Publication

deCODE genetics

First genetic locus for voice pitch

image: Dr. Kari Stefansson CEO of deCODE genetics and senior author on the paper, with Rosa B. Gisladottir first author. view more 

Credit: deCODE genetics

Reykjavik, Iceland. 9.. June 2023 - In a paper published today in Science Advances, an international team led by deCODE genetics, a subsidiary of Amgen, reveals the discovery of sequence variants in the gene ABCC9 that influence the pitch of voices.

Speaking is one of the most characteristic human behaviors, and yet the genetic underpinnings of voice and speech are largely unknown. In the first study of its kind, the scientists combined speech recordings from almost 13,000 Icelanders with data, in the sequence of the genome, to search for common variants in ABCC9 that are associated with a higher-pitched voice.

The scientists found that ABCC9 variants associate with higher voice pitch in both men and women. The same sequence variants are also linked to higher pulse pressure, a cardiovascular risk factor, highlighting links between voice pitch and health-related traits.

In addition to voice pitch, the study investigated the genetics of vowel acoustics.  While vowel sounds such as ah or ee are clearly influenced by culture and context, the scientists found that such measures contain a heritable component, which likely has to do with the shape of the vocal tract and its effect on vowel sounds.

The findings shed new light on diversity in voice and speech and contribute to a better understanding of the human vocal system.


Based in Reykjavik, Iceland, deCODE genetics, is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE is a wholly-owned subsidiary of Amgen (NASDAQ:AMGN).

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.